UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor antibody positive (AChR-Ab+) Acceptance by U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news